Tumor monocyte content predicts immunochemotherapy outcomes in esophageal adenocarcinoma
For inoperable esophageal adenocarcinoma (EAC), identifying patients likely to benefit from recently approved immunochemotherapy (ICI+CTX) treatments remains a key challenge. We address this using a uniquely designed window-of-opportunity trial (LUD2015-005), in which 35 inoperable EAC patients rece...
المؤلفون الرئيسيون: | Carroll, TM, Chadwick, JA, Owen, RP, White, MJ, Kaplinsky, J, Peneva, I, Frangou, A, Xie, PF, Chang, J, Roth, A, Amess, B, James, SA, Rei, M, Fuchs, HS, McCann, KJ, Omiyale, AO, Jacobs, B-A, Lord, SR, Norris-Bulpitt, S, Dobbie, ST, Griffiths, L, Ramirez, KA, Ricciardi, T, Macri, MJ, Ryan, A, Venhaus, RR, Van den Eynde, BJ, Karydis, I, Schuster-Böckler, B, Middleton, MR, Lu, X |
---|---|
مؤلفون آخرون: | LUD2015-005 Project Team |
التنسيق: | Journal article |
اللغة: | English |
منشور في: |
Cell Press
2023
|
مواد مشابهة
-
Immunochemotherapy for Richter syndrome: current insights
حسب: Puła B, وآخرون
منشور في: (2019-02-01) -
Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment
حسب: VPCP Toledo, وآخرون
منشور في: (2001-01-01) -
Immunotherapy and immunochemotherapy in combating visceral leishmaniasis
حسب: Ganesh Yadagiri, وآخرون
منشور في: (2023-05-01) -
Successful treatment of a primary uterine B-cell lymphoma with rituximab-CHOP immunochemotherapy
حسب: M. Egyed, وآخرون
منشور في: (2007-02-01) -
Treatment of B-cells non-Hodgkin lymphomas with combined immunochemotherapy: ability to treatment optimization
حسب: N. V. Smirnova, وآخرون
منشور في: (2015-12-01)